Crovalimab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.

Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.

Journal: Journal of comparative effectiveness research

Published: August 24, 2026

Clinical similarity in cost-comparison evaluations: a systematic review of current methods in NICE appraisals and the development of a framework for the formal assessment of clinical similarity.

Clinical similarity in cost-comparison evaluations: a systematic review of current methods in NICE appraisals and the development of a framework for the formal assessment of clinical similarity.

Journal: BMJ open

Published: July 21, 2026

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

Journal: Expert review of clinical pharmacology

Published: May 29, 2026

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.

Journal: Journal of clinical medicine

Published: March 26, 2026

Mapping of C5-Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition.

Mapping of C5-Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition.

Journal: Immunology

Published: February 26, 2026

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.

Journal: Hematology (Amsterdam, Netherlands)

Published: January 29, 2026

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: January 12, 2026

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Journal: Kidney medicine

Published: January 08, 2026

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency.

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency.

Journal: British journal of clinical pharmacology

Published: December 22, 2025

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Journal: Cells

Published: December 02, 2025

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

Journal: Kidney & blood pressure research

Published: November 28, 2025

Donor-Derived Cell-Free DNA (dd-cfDNA) as an Early Noninvasive Biomarker of Graft Injury in Pig-to-Monkey Islet Xenotransplantation.

Donor-Derived Cell-Free DNA (dd-cfDNA) as an Early Noninvasive Biomarker of Graft Injury in Pig-to-Monkey Islet Xenotransplantation.

Journal: Xenotransplantation

Published: November 11, 2025

Showing 1-12 of 62

Last Updated: 09/26/2026